SymbolENVB
NameENVERIC BIOSCIENCES, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address245 FIRST STREET,RIVERVIEW II,18TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States
Telephone+1 617 - 444-8400
Fax
Email
Websitehttps://www.enveric.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0000890821
Description

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Additional info from NASDAQ:
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

2026-08-14 20:16

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Read more
2026-08-14 20:15

(19% Negative) ENVERIC BIOSCIENCES, INC. (ENVB) Announces Delay in treatments Trials for EB-003 Due to Safety Review, Efficacy Assessment

Read more
2026-08-14 20:05

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Read more
2026-08-14 11:11

New Form SCHEDULE 13G - Enveric Biosciences, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003572 <b>Size:</b> 10 KB

Read more
2026-08-13 13:41

New Form SCHEDULE 13G/A - Enveric Biosciences, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001493152-26-037652 <b>Size:</b> 12 KB

Read more
2026-08-05 12:01

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Read more
2026-08-05 12:00

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Read more
2026-07-28 12:01

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Read more
2026-06-29 13:09

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Read more
2026-06-29 12:00

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Read more